Your session is about to expire
← Back to Search
Zafirlukast for Ovarian Cancer
Study Summary
This trial is testing whether or not Zafirlukast can help to prevent ovarian cancer tumor activity in people who have already been diagnosed with the disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have side effects from cancer treatment, but they are mild except for hair loss or nerve issues.I am 18 years old or older.My CA-125 levels have doubled without signs of cancer on scans.I am not pregnant or breastfeeding.I am currently on blood thinner medication.I haven't had chemotherapy or radiotherapy in the last 4 weeks, but may be on a stable dose of certain maintenance medications.I am currently taking certain blood thinners or anti-inflammatory medications daily.My ovarian tumor is not primarily cancerous or is a specific rare type.I've completed initial chemotherapy and surgery for my cancer without it getting worse.I can swallow pills.I am 18 years old or older.I am not taking any drugs that affect CYP2C9 enzyme activity.I am a woman who can become pregnant and agree to use birth control during the study.I have been diagnosed with ovarian, fallopian tube, or peritoneal cancer.I do not have brain metastases.You have had allergic reactions to drugs similar to zafirlukast.I do not have any unmanaged ongoing illnesses.You are expected to live for at least 4 more months.My blood counts and kidney and liver functions are within normal ranges.I can take care of myself but might not be able to do heavy physical work.
- Group 1: Zafirlukast
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
To what extent is the trial participant pool currently comprised?
"Affirmative, clinicaltrials.gov has evidence indicating that this medical experimentation is currently recruiting participants. This trial was initially posted on June 24th 2020 and the listing was most recently revised on November 11th 2022; 30 patients are expected to be recruited from a single site."
Has the Food and Drug Administration (FDA) given clearance to Zafirlukast?
"With Phase 2 trial data suggesting some safety, our team at Power has scored Zafirlukast's security a 2. Unfortunately, no efficacy findings have been reported yet."
Could you outline any other experiments conducted with Zafirlukast?
"Currently, only 1 clinical trial is active for Zafirlukast. None of these have reached Phase 3 yet. Most studies are based in Boston, MA but one other location is also running trials for this medication."
Does this research endeavor have room for additional participants?
"Affirmative, clinicaltrials.gov data affirms that this research study is actively searching for participants; it was first posted on June 24th 2020 and last updated November 11th 2022. 30 patients need to be recruited across a single medical site."
Share this study with friends
Copy Link
Messenger